SURMOUNT trial programme: difference between revisions
Diff·revision 4 → 5·05:57, 8 Sep 2024
Difference between revision 4 and revision 5 of SURMOUNT trial programme. 4 lines changed; the page grew by 479 bytes.
| Revision 4 — 16:54, 28 Aug 2024 SurmountSurma (talk) serial comma per PP:MOS 2,057 bytes ±0 | Revision 5 — 05:57, 8 Sep 2024 StubSorterBot (talk) bot: expand DOI to full citation 2,536 bytes +479 | ||
|---|---|---|---|
| 10 | Mean weight change was −15.0%, −19.5% and −20.9% at the three doses against −3.1% on placebo. Both arms received lifestyle counselling, so the placebo figure is not a no-treatment baseline; see [[Placebo-adjusted effect]].{{r|jastreboff2022}} | 10 | Mean weight change was −15.0%, −19.5% and −20.9% at the three doses against −3.1% on placebo. Both arms received lifestyle counselling, so the placebo figure is not a no-treatment baseline; see [[Placebo-adjusted effect]].{{r|jastreboff2022}} |
| 11 | 11 | ||
| + | 12 | SURMOUNT-2 studied participants with obesity and type 2 diabetes and reported smaller reductions — −12.8% and −14.7% at 10 and 15 mg against −3.2% — reproducing the attenuation of weight response in diabetes seen across this field.{{r|garvey2023}} | |
| + | 13 | ||
| 12 | == Constituent trials == | 14 | == Constituent trials == |
| 13 | | Trial | Population | Duration | Result at highest dose | | 15 | | Trial | Population | Duration | Result at highest dose | |
| ⋮ | ⋮ | ||
| 19 | 21 | ||
| 20 | SURMOUNT-4 is the counterpart of STEP 4 and addresses the same question: what happens when treatment stops. Participants randomised to placebo after a lead-in regained a substantial proportion of the weight lost. See [[Weight regain after discontinuation]].{{r|garvey2023}} | 22 | SURMOUNT-4 is the counterpart of STEP 4 and addresses the same question: what happens when treatment stops. Participants randomised to placebo after a lead-in regained a substantial proportion of the weight lost. See [[Weight regain after discontinuation]].{{r|garvey2023}} |
| + | 23 | ||
| + | 24 | SURMOUNT-3 shows that a lifestyle lead-in does not exhaust the available effect: participants who had already lost weight on intensive lifestyle intervention lost further weight on active treatment.{{r|jastreboff2022}} | |
| 21 | 25 | ||
| 22 | == References == | 26 | == References == |